...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in therapy. >Breakthrough Cancer Pain (BTe-P): a Synthesis of Taxonomy, Pathogenesis, Therapy, and Good Clinical Practice in Adult Patients in Italy
【24h】

Breakthrough Cancer Pain (BTe-P): a Synthesis of Taxonomy, Pathogenesis, Therapy, and Good Clinical Practice in Adult Patients in Italy

机译：突破性癌痛（BTe-P）：意大利成年患者的分类学，发病机制，治疗方法和良好临床实践的综合

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pain presents in 80% of patients with advanced cancer, and 30% have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal.
机译：80％的晚期癌症患者出现疼痛，而30％的患者由于强度波动而出现疼痛加剧的时期，这被称为突破性癌症疼痛（BTcP）。 BTcP是高强度，持续时间短的疼痛，每天发作数次，对治疗无反应。 BTcP的临床方法是可变的。进行了文献回顾，为临床医生和从业人员提供了对正在进行的关于BTcP的科学辩论的合理综合，并为意大利成年患者使用BTcP的最佳临床方法提供了基础。数据显示，应仔细监测昼夜节律性疼痛加重，并在可能的情况下区分背景性疼痛（BP），剂量终止效应和BTcP的波动。在临床实践中，应在所有护理环境中对BTcP进行监测，并且每个护理机构必须拥有批准用于BTcP的所有药物和产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号